Should rosuvastatin be withdrawn from the market?
Florentinus
Stefan R
SR
Heerdink
Eibert R
ER
Klungel
Olaf H
OH
de Boer
Anthonius
A
D017277:Drug Approval; D004363:Drug Utilization; D005464:Fluorobenzenes / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D009426:Netherlands; D011358:Product Surveillance, Postmarketing; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000009:adverse effects* / Q000627:therapeutic use
D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium